{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"301"},{"groupId":"OG001","value":"288"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"314"},{"groupId":"OG001","value":"296"}],"units":"Participants"}],"description":"An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a pre-existing condition that was temporally associated with the use of the Sponsor's product was also an AE. The number of participants who experienced ≥1 AE is presented.","groups":[{"description":"Participants received pembrolizumab 200 mg IV on Day 1 of every 21-day (3-week) cycle for up to 35 administrations (up to approximately 25 months).","id":"OG000","title":"Pembrolizumab"},{"description":"Participants received Investigator's choice of paclitaxel 80-100 mg/m\\^2 IV on Days 1, 8, and 15 of every 28-day (4-week) cycle, OR docetaxel 75 mg/m\\^2 IV on Day 1 of every 21-day (3-week) cycle, OR irinotecan 180 mg/m\\^2 IV on Day 1 of every 14-day (2-week) cycle (up to approximately 19 months).","id":"OG001","title":"Chemotherapy"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The analysis population consisted of all randomized participants who received at least 1 dose of study treatment. Participants were included in the treatment group to which they were randomized.","reportingStatus":"POSTED","timeFrame":"Through End-of-Trial Analysis data cutoff date of 14-Mar-2022 (up to approximately 6 years)","title":"Number of Participants Experiencing an Adverse Event (AE)","type":"SECONDARY","unitOfMeasure":"Participants"}